Zhejiang Hisoar Pharmaceutical Hits Day High with 7% Intraday Surge

Zhejiang Hisoar Pharmaceutical Co., Ltd. has experienced a notable surge today, with the stock rising by 7.0% and reaching an intraday high of CNY 6.93. This performance stands in contrast to the China Shanghai Composite, which saw a modest increase of 1.78% on the same day. Despite today's gains, the company's longer-term performance metrics reveal a more complex picture. Over the past year, Zhejiang Hisoar has achieved a return of 38.71%, significantly outperforming the Shanghai Composite's 15.17%. However, the stock has faced challenges in the short term, with a decline of 3.51% over the past week and a more substantial drop of 10.3% over the last month. Financial indicators suggest that the company is grappling with low profitability, as evidenced by a Return on Capital Employed (ROCE) of just 2.16%. Additionally, the company has reported a negative net profit of CNY -83.69 million in its latest quarterly results, reflecting a significant decline of 162.86%. With a market capitalization of CNY 11,906 million, Zhejiang Hisoar remains a midcap player in the pharmaceuticals and biotechnology sector, navigating a challenging financial landscape.